Form 4: Artelo Biosciences Director Acquires Convertible Promissory Note

Director Tamara A. Favorito acquired a convertible promissory note from Artelo Biosciences, Inc. on May 1, 2025, which may be converted into common stock or warrants.

Summary

• On May 1, 2025, Tamara A. Favorito, a director of Artelo Biosciences, Inc., acquired a convertible promissory note from the company.
• The note, with a principal amount of $25,000, accrues interest at 12% per annum, increasing to 20% upon an Event of Default.
• The note matures on October 28, 2025.
• At maturity, Favorito has the option to convert the unpaid principal and accrued interest into common stock at a conversion price of $1.29 per share, subject to a minimum price of $1.04 per share.
• Any portion of the note not voluntarily converted will be automatically converted into a warrant to purchase common stock at a conversion price of $0.125 per share, with an exercise price equal to the Minimum Price.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director is investing in the company, which is a good sign, but the high interest rate upon default is a concern.

Positives

• The investment by a director signals confidence in the company's prospects.
• The convertible note provides Artelo Biosciences with additional capital.

Risks

• The potential for dilution of existing shareholders if the note is converted into common stock.
• The increased interest rate of 20% upon an Event of Default could strain the company's finances.

Future Outlook

The future depends on whether the Reporting Person elects Voluntary Conversion, and the performance of the company's stock price.

Industry Context

Convertible notes are a common financing tool for small-cap companies, allowing them to raise capital without immediately diluting existing shareholders.

Comparison to Industry Standards

• Comparable companies in the biotech sector often use convertible notes to fund research and development.
• The terms of this convertible note, including the interest rate and conversion price, appear to be within the typical range for similar financings in the industry.
• The conversion price of $1.29 is a premium to the minimum price of $1.04, which is a common feature to incentivize conversion.

Related Party Transactions

• The issuance of the convertible note to Director Tamara A. Favorito is a related party transaction.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• The company's financial stability could be affected by the interest payments on the note, especially if an Event of Default occurs.

Key Dates

Keywords

convertible note, Artelo Biosciences, director, Form 4, insider transaction, ARTL, common stock, warrant